^
    1d
    A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    Tazverik (tazemetostat)
    1d
    Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. (PubMed, Blood Adv)
    In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • FANCE (FA Complementation Group E)
    1d
    Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. (PubMed, Am J Hematol)
    This multitargeted regimen addresses the biologic heterogeneity of MCL and permits flexible MRD-guided decisions on consolidation and maintenance. Trial Registration: ClinicalTrials.gov identifier: NCT04626791.
    Journal
    |
    clonoSEQ®
    |
    Rituxan (rituximab) • cytarabine • bortezomib • Calquence (acalabrutinib)
    2d
    Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=106, Completed, Alliance for Clinical Trials in Oncology | Phase classification: P2 --> P1
    Phase classification
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    lenalidomide • Zydelig (idelalisib)
    3d
    Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P2, N=11, Terminated, University of Washington | N=20 --> 11 | Trial completion date: Jul 2028 --> May 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> May 2026; The trial closed early due to slow accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Zynlonta (loncastuximab tesirine-lpyl) • AMG 211
    6d
    BELLWAVE-001: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (clinicaltrials.gov)
    P1/2, N=190, Active, not recruiting, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    nemtabrutinib (MK-1026)
    6d
    Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=105, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2023 --> Sep 2028
    Enrollment closed • Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    7d
    Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1, N=85, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | N=50 --> 85
    Enrollment change
    7d
    Evaluating Different Doses of Orelabrutinib in MCL (clinicaltrials.gov)
    P2, N=40, Completed, InnoCare Pharma Inc. | Recruiting --> Completed
    Trial completion
    |
    Inokai (orelabrutinib)
    8d
    Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Completed, Northwestern University | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib)
    9d
    LncRNA IRAIN inhibits mantle cell lymphoma progression by inducing cell cycle arrest and apoptosis: an in vitro study. (PubMed, Sci Rep)
    Collectively, these findings suggest that IRAIN may participate in the regulation of proliferation, apoptosis, and cell cycle progression in MCL cells, potentially through modulation of LSD1. These results provide preliminary experimental evidence for further understanding the potential biological function of IRAIN in MCL.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • KDM1A (Lysine Demethylase 1A) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    10d
    A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=106, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Inokai (orelabrutinib)